TY - JOUR
T1 - Re-infused autologous graft natural killer cells correlates with absolute lymphocyte count recovery after autologous stem cell transplantation
AU - Porrata, Luis F.
AU - Gastineau, Dennis A.
AU - Padley, Douglas
AU - Bundy, Kevin
AU - Markovic, Svetomir N.
PY - 2003/6/1
Y1 - 2003/6/1
N2 - Early absolute lymphocyte count (ALC) has been reported to be a powerful prognostic indicator of survival after autologous stem cell transplantation (ASCT). One possible source affecting ALC recovery includes the re-infused autologous graft lymphocytes (AGL). To assess if the re-infused AGL correlate with ALC recovery post-ASCT, we conducted a pilot study to identify which of the re-infused AGL subsets is most associated with day 15 ALC recovery in three patients with multiple myeloma and four patients with non-Hodgkin's lymphoma. Using the Spearman rank correlation coefficient analysis (r), we compared absolute numbers of CD3, CD4, CD8, CD19, and CD16+/CD56+ cells/kg of body weight from the apheresis product with ALC (cells/μl) at day 15 post-ASCT. The main lymphocyte subsets identified in the apheresis product were T cells and NK cells. There was no strong correlation between T or B cells from the apheresis product compared with the ALC at day 15 post-ASCT (CD3, r = 0.21; CD4, r = 0.32; CD8, r = 0.39; and CD19, r = 0.14). However, there was good correlation between NK cells from the apheresis product compared with ALC at day 15 post-ASCT (CD16+/CD56+/CD3-, r = 0.77). These data provide preliminary evidence that the number of re-infused autologous graft NK cells in the apheresis product significantly affect ALC recovery early post-ASCT. However, given the small sample size, our results are primarily hypothesis generating and subject of further research.
AB - Early absolute lymphocyte count (ALC) has been reported to be a powerful prognostic indicator of survival after autologous stem cell transplantation (ASCT). One possible source affecting ALC recovery includes the re-infused autologous graft lymphocytes (AGL). To assess if the re-infused AGL correlate with ALC recovery post-ASCT, we conducted a pilot study to identify which of the re-infused AGL subsets is most associated with day 15 ALC recovery in three patients with multiple myeloma and four patients with non-Hodgkin's lymphoma. Using the Spearman rank correlation coefficient analysis (r), we compared absolute numbers of CD3, CD4, CD8, CD19, and CD16+/CD56+ cells/kg of body weight from the apheresis product with ALC (cells/μl) at day 15 post-ASCT. The main lymphocyte subsets identified in the apheresis product were T cells and NK cells. There was no strong correlation between T or B cells from the apheresis product compared with the ALC at day 15 post-ASCT (CD3, r = 0.21; CD4, r = 0.32; CD8, r = 0.39; and CD19, r = 0.14). However, there was good correlation between NK cells from the apheresis product compared with ALC at day 15 post-ASCT (CD16+/CD56+/CD3-, r = 0.77). These data provide preliminary evidence that the number of re-infused autologous graft NK cells in the apheresis product significantly affect ALC recovery early post-ASCT. However, given the small sample size, our results are primarily hypothesis generating and subject of further research.
KW - Absolute lymphocyte count
KW - Autologous graft lymphocyte subsets
KW - Autologous stem cell transplantation
KW - Natural killer cells
UR - http://www.scopus.com/inward/record.url?scp=0037409663&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0037409663&partnerID=8YFLogxK
U2 - 10.1080/1042819031000077089
DO - 10.1080/1042819031000077089
M3 - Article
C2 - 12854901
AN - SCOPUS:0037409663
SN - 1042-8194
VL - 44
SP - 997
EP - 1000
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
IS - 6
ER -